Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results
Highlights
– PREVENT-TAHA8, a phase 3 randomized trial, tested intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ‑MSCs) given 3–7 days after first ST-elevation myocardial infarction (STEMI) in patients with LVEF <40%.
– WJ-MSCs significantly reduced incidence of heart failure (HR 0.43; 95% CI 0.21–0.89; P=0.024) and readmission for heart failure (HR 0.22; 95% CI 0.06–0.74; P=0.015), and improved 6-month LVEF (mean adjusted difference ≈5.9%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.